|
|
|
|
|
|
Sponsored by: |
Baskent University |
Information provided by: | Baskent University |
ClinicalTrials.gov Identifier: | NCT00290394 |
The purpose of this study was to determine the effects of rosiglitazone in normotensive type 2 diabetic patients with regard to its blood-pressure–reducing effects.
Condition | Intervention | Phase |
Diabetes Mellitus, Type 2 |
Drug: rosiglitazone(drug), blood pressure lowering effect |
Phase IV |
MedlinePlus related topics: | Diabetes |
Drug Information available for: | Rosiglitazone Rosiglitazone Maleate |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Study of PPAR Gamma Agonist-Rosiglitazone in Normotensive Type 2 Diabetics With Ambulatory Blood Pressure Monitoring |
Estimated Enrollment: | 25 |
Study Start Date: | March 2004 |
Estimated Study Completion Date: | August 2004 |
The first study to evaluate the effects of troglitazone on blood pressure in humans was published recently, which demonstrated a 5/4 mm Hg reduction in ambulatory blood pressure in 18 nondiabetic obese subjects after 12 weeks’ treatment. Another study in 18 hypertensive subjects with diabetes mellitus showed an 18/12 mm Hg decline in office blood pressure after 8 weeks of treatment.
Ages Eligible for Study: | 49 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | KA03/181 |
First Received: | February 9, 2006 |
Last Updated: | February 9, 2006 |
ClinicalTrials.gov Identifier: | NCT00290394 |
Health Authority: | Turkey: Ministry of Health |
|
|
|
|